Browsing Tag
clinical trial results
13 posts
Cynata Therapeutics secures $8.1m funding after promising results from diabetic foot ulcers trial
Cynata Therapeutics Limited, a clinical-stage biotechnology company listed on the Australian Securities Exchange (ASX: CYP), has raised A$8.1…
Everest Medicines’ EVER001 shows promising Phase 1b/2a trial results for autoimmune kidney disease treatment
Everest Medicines has announced promising preliminary results from its ongoing Phase 1b/2a clinical trial of EVER001, a next-generation…
Janux Therapeutics advances prostate cancer treatment as stock soars
Janux Therapeutics made headlines with an extraordinary 54% surge in after-hours trading on Monday, bringing its stock price…
ENCell announces promising results from Phase 1 CMT1A trial of EN001
ENCell Co., Ltd., a South Korean biotech leader specializing in Cell and Gene Therapy (CGT), has unveiled promising…
Agios Pharmaceuticals’ mitapivat meets primary endpoint in Phase 3 thalassemia trial
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), renowned for its innovative therapies in cellular metabolism and pyruvate kinase (PK) activation,…
Novartis’ atrasentan shows significant reduction in proteinuria in seasonal allergic rhinitis patients
Novartis presented compelling interim results from the Phase III ALIGN study evaluating the efficacy of atrasentan, an investigational…
Zealand Pharma announces promising results from dapiglutide trial for obesity treatment
Zealand Pharma A/S (Nasdaq: ZEAL), a pioneer in peptide-based drug development, has shared topline results from its DREAM…
Eupraxia Pharmaceuticals announces promising results for EP-104GI in eosinophilic esophagitis trial
Eupraxia Pharmaceuticals Inc., listed on both TSX and NASDAQ under the ticker EPRX, has revealed encouraging results from…
Roche’s CT-388 shows promising results in Phase I trial for obesity and Type 2 diabetes treatment
Roche has announced positive outcomes from the Phase I clinical trial of CT-388, a novel dual GLP-1/GIP receptor…
Lyra Therapeutics reports disappointing results for LYR-210 in Phase 3 chronic rhinosinusitis trial
Lyra Therapeutics, Inc. (Nasdaq: LYRA), dedicated to advancing treatments for chronic rhinosinusitis (CRS), announced that its Phase 3…